Alnylam Pharmaceuticals Inc.
), a biopharmaceutical company, is focused on the development of
novel therapeutics based on RNA (ribo nucleic acid) interference
(RNAi). The company is developing several candidates using this
technology for the treatment of multiple diseases.
ACTELION LTD (ALIOF): Get Free Report
ALNYLAM PHARMA (ALNY): Free Stock Analysis
ENDO PHARMACEUT (ENDP): Free Stock Analysis
MEDICINES CO (MDCO): Free Stock Analysis
To read this article on Zacks.com click here.
Although most of the candidates at Alnylam are in early or
mid-stages of development the company has progressed well with
its pipeline in the recent past. ALN-PCSsc, a subcutaneously
administered RNAi therapeutic, is an important candidate at
Alnylam under the company's ALN-PCS RNAi program. The candidate
is being developed for the treatment of hypercholesterolemia.
Earlier this year, Alnylam had entered into a global alliance
The Medicines Co.
) for the development and commercialization of the ALN-PCS RNAi
program. The companies announced new data from non-human primate
studies which revealed that ALN-PCSsc was successful in reducing
PCSK9 by up to 90%. The candidate was also successful in reducing
low-density lipoprotein (LDL) cholesterol in the absence of
statins by up to 68%.
Alnylam and The Medicines Co. intend to file an investigative new
drug application for the candidate in the U.S. towards the end of
As per the collaboration between the two companies, Alnylam will
conduct pre-clinical and phase I studies following which The
Medicines Co. will take up funding and development for the rest
of the ALN-PCS program. The Medicines Co. will also be
responsible for the commercialization of the ALN-PCS program, if
We are encouraged by the pipeline progress at Alnylam. We expect
investor focus to remain on the company's pipeline.
Alnylam presently carries a Zacks Rank #4 (Sell). Stocks such as
Endo Health Solutions Inc.
) currently look better positioned with a Zacks Rank #1 (Strong